We are live on
!
Find out more
HF
HRT Financial Portfolio holdings
AUM
$40.1B
1-Year Est. Return
58.22%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+58.22%
3 Year Est. Return
+133.11%
5 Year Est. Return
+158.39%
10 Year Est. Return
+582.81%
AUM
$13.7B
AUM Growth
+$3.66B
(+37%)
Cap. Flow
+$2.6B
Cap. Flow
% of AUM
18.96%
Top 10 Holdings %
Top 10 Hldgs %
51.2%
Holding
3,395
New
1,045
Increased
548
Reduced
607
Closed
1,119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.94B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$377M |
| 3 |
Linde
LIN
|
+$287M |
| 4 |
Apple
AAPL
|
+$112M |
| 5 |
Direxion Daily Semiconductor Bear 3X ETF
SOXS
|
+$106M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$140M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$139M |
| 3 |
T-Mobile US
TMUS
|
+$137M |
| 4 |
lululemon athletica
LULU
|
+$115M |
| 5 |
VMW
VMware, Inc
VMW
|
+$108M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.67% |
| 2 | Consumer Discretionary | 5.65% |
| 3 | Financials | 5.29% |
| 4 | Healthcare | 4.91% |
| 5 | Materials | 4.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SCS
1326
DELISTED
Steelcase
SCS
| $535K | ﹤0.01% |
+39,585
| New | +$470K |
|
1327
ProShares UltraShort MSCI Brazil Capped
BZQ
$2.51M
| $533K | ﹤0.01% |
13,292
+3,281
| +33% | +$168K |
|
1328
Schwab US Large-Cap Growth ETF
SCHG
$62.8B
| $533K | ﹤0.01% |
+25,724
| New | +$498K |
|
1329
Cogent Biosciences
COGT
$7.24B
| $530K | ﹤0.01% |
+90,215
| New | +$691K |
|
1330
PUT
Alphabet (Google) Class A
GOOGL
$4.33T
| $530K | ﹤0.01% |
3,800
-37,100
| -91% | -$4.98M |
|
|
AVNS
1331
DELISTED
Avanos Medical
AVNS
| $529K | ﹤0.01% |
+23,595
| New | +$487K |
|
1332
CALL
Match Group
MTCH
$8.55B
| $529K | ﹤0.01% |
+14,500
| New | +$490K |
|
1333
MicroSectors Oil & Gas Exp. & Prod. 3x Leveraged ETN
OILU
$60.8M
| $527K | ﹤0.01% |
+14,974
| New | +$574K |
|
1334
Celldex Therapeutics
CLDX
$3.28B
| $525K | ﹤0.01% |
13,243
-8,362
| -39% | -$246K |
|
1335
Nomad Foods
NOMD
$1.68B
| $524K | ﹤0.01% |
+30,951
| New | +$479K |
|
1336
Synaptics
SYNA
$4.15B
| $524K | ﹤0.01% |
4,595
-108,764
| -96% | -$10.8M |
|
1337
Prime Medicine
PRME
$559M
| $523K | ﹤0.01% |
+59,116
| New | +$455K |
|
1338
Ginkgo Bioworks
DNA
$521M
| $521K | ﹤0.01% |
7,718
-36,432
| -83% | -$2.23M |
|
1339
iShares MSCI Malaysia ETF
EWM
$325M
| $521K | ﹤0.01% |
24,544
+10,272
| +72% | +$216K |
|
1340
Keros Therapeutics
KROS
$221M
| $521K | ﹤0.01% |
+13,122
| New | +$411K |
|
1341
State Street SPDR Portfolio High Yield Bond ETF
SPHY
$11.6B
| $521K | ﹤0.01% |
+22,325
| New | +$504K |
|
1342
Opko Health
OPK
$1.02B
| $518K | ﹤0.01% |
343,605
+89,275
| +35% | +$129K |
|
1343
AbCellera Biologics
ABCL
$2.12B
| $517K | ﹤0.01% |
90,562
+28,361
| +46% | +$131K |
|
1344
ProShares Short Bitcoin Strategy ETF
BITI
$119M
| $516K | ﹤0.01% |
7,854
+5,917
| +305% | +$471K |
|
1345
American Vanguard Corp
AVD
$68.9M
| $514K | ﹤0.01% |
46,892
+29,769
| +174% | +$297K |
|
1346
Kennametal
KMT
$2.52B
| $514K | ﹤0.01% |
19,967
-73,018
| -79% | -$1.76M |
|
1347
Pliant Therapeutics
PLRX
$65M
| $514K | ﹤0.01% |
+28,430
| New | +$432K |
|
1348
CALL
Upstart Holdings
UPST
$3.03B
| $514K | ﹤0.01% |
+12,600
| New | +$384K |
|
1349
PUT
General Motors
GM
$76.8B
| $513K | ﹤0.01% |
+14,300
| New | +$442K |
|
1350
UWM Holdings
UWMC
$434M
| $513K | ﹤0.01% |
+71,838
| New | +$406K |
|
Similar funds
DB
HRT Financial's Q4 2023 Portfolio in Review
As of Q4 2023, HRT Financial held 3,395 positions worth $13.7B, up 37% from $10B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
HRT Financial deployed $2.6B of net new capital in Q4 2023, opening 1,045 new positions and adding to 548 existing holdings. Its largest new stake was Linde: 727,095 shares worth $299M.
By sector, the portfolio is most concentrated in Technology at 8.7% of assets, down from 11% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Broadcom, an estimated $83.7M trimmed.
- HRT Financial's largest Q4 2023 buy was Linde: 727,095 shares worth $299M.
- HRT Financial added most to State Street SPDR S&P 500 ETF Trust in Q4 2023, an estimated $1.94B increase.
- HRT Financial's biggest Q4 2023 reduction was Broadcom, cutting an estimated $83.7M.
- HRT Financial fully exited Newmont in Q4 2023, selling an estimated $140M.
- HRT Financial's ten largest holdings make up 51% of its $13.7B portfolio in Q4 2023.
- HRT Financial opened 1,045 new positions and closed 1,119 in Q4 2023.
- HRT Financial's portfolio value rose 37% quarter-over-quarter to $13.7B.
Based on HRT Financial's 13F filing for Q4 2023, filed 9 Feb 2024.